Introduction:
During the past decade, skin biopsy has become a popular diagnostic technique for investigating small nerve fibers. It allows general practitioners and non-specialists like diabetologists and orthopedics doctors to diagnose sensory neuropathy (thereby avoiding delayed or incorrect diagnosis), find the etiology, and focus treatment, especially for neuropathic pain or nerve pain.
What Is Skin Biopsy?
Skin biopsy is a safe, painless, and cheap technique for evaluating small nerve fibers. The density of these fibers can be evaluated by using bright field microscopy in sections cut from the specimen and adequately immunostained with antibodies against markers expressed by peripheral nerve fibers. Skin biopsy can also be performed again within the same nerve territory to calculate the natural progression of the sensory neuropathy and the effect of treatments like steroids or immunoglobulin.
The positive predictive value of skin biopsy in diagnosing small fiber neuropathy is approximately 93 percent. Specificity is 97 percent, and sensitivity ranges from 69 to 82 percent. Skin biopsy has recently helped in the diagnosis of morphological and quantitative alterations in skin innervation earlier than neurophysiological tests. It has also helped to show the progression of neuropathy.
Comparative studies have emphasized the role of skin biopsy in diagnosing small fiber neuropathy. An analysis of patients with small-fiber neuropathy has demonstrated that the density of unmyelinated intraepidermal nerve fibers can be low. Once small fiber neuropathy has been diagnosed further tests can be performed to define its etiology.
A study documented that in 42 percent of patients with small fiber neuropathy diagnosed by skin biopsy, the oral glucose tolerance testing showed an unknown impaired glucose tolerance. In diabetic patients, the extent of intraepidermal nerve fiber loss increases with the duration of the disease and can be correlated with raised warm thresholds, indicating that these two parameters may be the major indicators of small fiber neuropathy.
What Is Small Fiber Neuropathy?
Small fiber neuropathy (SFN) mainly alters small myelinated A-delta fibers and unmyelinated C fibers. These fibers help to transmit pain and temperature sensations and are involved in autonomic functions. Symptoms of SFN often include:
-
Tingling or numbness.
-
Chronic pain and burning sensations in the feet or hands.
-
Allodynia (pain caused by a stimulus that does not usually provoke pain).
-
Autonomic symptoms like gastrointestinal disturbances, abnormal sweating, and heart rate discrepancies.
Causes of SFN can vary such as autoimmune diseases, diabetes, infections, genetic mutations, and idiopathic causes (unknown origin).
What Are Traditional Diagnostic Approaches?
Diagnosing SFN traditionally depends on patient history, clinical examination, and nerve conduction studies. However, these methods mainly assess large fiber function and may not detect small fiber abnormalities. Quantitative sensory testing (QST) can measure small fiber function but lacks specificity and can not always confirm the diagnosis. This is where skin biopsy becomes essential.
How Is Skin Biopsy Performed for Small Fiber Neuropathy?
Procedure:
-
The biopsy site (usually the lower leg) is cleaned and numbed with a local anesthetic.
-
A small punch tool, generally three millimeters in diameter helps to remove a skin sample.
-
The sample is sectioned, fixed, and stained for immunohistochemical analysis.
-
The sample is observed under a microscope to assess the density and morphology of small nerve fibers.
Importance:
-
Nerve Fiber Density: Decreased intraepidermal nerve fiber density (IENFD) is a primary indicator of SFN. A lower IENFD compared to normative data suggests the diagnosis.
-
Morphology of Nerve Fiber: Abnormalities in nerve fiber structure suggest SFN.
-
Validation of Symptoms: Skin biopsy leads to objective evidence supporting patients' symptoms, leading to a definitive diagnosis.
Advantages of Skin Biopsy:
-
Minimally Invasive: The procedure is straightforward and involves minimal discomfort.
-
High Sensitivity and Specificity: Skin biopsy helps to small fiber pathology accurately, leading to a reliable diagnosis.
-
Early Detection: It can identify SFN at an early stage, helping in timely intervention.
-
Comprehensive Assessment: It can detect structural abnormalities in the skin's nerve.
Post-Biopsy Complications:
Post-procedure care includes maintaining the biopsy site clean and dry to prevent infection. Patients might experience mild discomfort, which can be treated with over-the-counter pain medications. Results are usually available within a few weeks, after which further management strategies can be evaluated.
How Is Small Fiber Neuropathy Managed?
After diagnosis, managing SFN involves addressing the underlying cause and symptomatic treatment. Options include:
-
Medications like anticonvulsants, pain relievers, and antidepressants can help manage symptoms.
-
Lifestyle modifications involvinga balanced diet, regular exercise, and maintaining optimal blood glucose levels in diabetic patients.
-
Therapiesincluding physical therapy, transcutaneous electrical nerve stimulation (TENS), and acupuncture may provide additional relief.
Skin biopsy has revolutionized the diagnosis of small fiber neuropathy, providing a reliable, minimally invasive, and accurate method to assess small nerve fiber damage. Skin biopsy helps guide appropriate management and improve patient outcomes, by ensuring prompt and precise diagnosis. As the understanding of SFN is continuously evolving, skin biopsy remains an integral part of the diagnostic process, providing hope and clarity to those affected by this challenging condition.
What Are the Other Clinical Uses of Skin Biopsy?
Skin biopsy has shown that unmyelinated axons can cause neuropathies that were previously thought to affect large nerve fibers only like in diseases where there is loss of skin nerves predicts autonomic failure and worse outcome. Skin biopsy is also useful in the diagnostic work-up of demyelinating neuropathies. In individuals with immune-mediated neuropathy caused by antibodies against myelin-associated glycoprotein, certain deposits of immunoglobulin (IgM) and complement have been identified in myelinated skin nerves. In vasculitic neuropathy, perivascular infiltrating cells can be demonstrated around dermal vessels. In inherited neuropathies, such as Charcot-Marie-Tooth disease, identifying large myelinated fibers in the skin can lead to the same pathological and molecular biological information.
Conclusion:
A skin biopsy must be considered in the diagnostic work-up of patients with symptoms suggestive of small fiber neuropathy (like prickling, burning, or deep and aching pains in the feet). However, with normal neurophysiological test results and in patients with autonomic neuropathy. Further, it can demonstrate subclinical neuropathy in individuals at risk, like those with diabetes. Skin biopsy can help diagnose sensory mononeuropathy when nerve conduction studies cannot be performed. Finally, follow-up skin biopsies allow the progression of neuropathy and the efficacy of treatments to be monitored.
